Posts tagged as: IGXT news back to homepage

IntelGenx Reports Positive Results in Anti-Migraine Study IntelGenx Reports Positive Results in Anti-Migraine Study(0)

Quebec, Canada-based biotech IntelGenx Corp. (TSX-V:IGX) (OTCBB:IGXT) announced this morning the completion of the pivotal bioequivalence study for a novel oral thin-film formulation of Rizatriptan, the active drug in migraine medication Maxalt-MLT® orally disintegrating tablets.  In December 2011, IntelGenx was approved by Health Canada to conduct a pivotal bioequivalence study to determine if IntelGenx’ product is safe and bioequivalent with the U.S. Food and Drug Administration approved reference product.  Maxalt-MLT® is a leading branded anti-migraine product manufactured by Merck & Co. (NYSE: MRK). Read More

IntelGenx Stock Chart Analysis Video IntelGenx Stock Chart Analysis Video(0)

A “stock to watch” this week, IntelGenx has had two great days so far. Momentum has gripped the stock with volume surging, keeping it on radar to possibly test resistance around 90 cents.

IntelGenx has been the focus of several articles across the web recently as it is slated for an FDA decision this month. Attention is coming to the play with volume steadily increasing in the first days of November bringing a sharp rise in share value.

IntelGenx is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. IntelGenx uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastrointestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. IntelGenx’ research and development pipeline includes products for the treatment of severe depression, hypertension, erectile dysfunction, benign prostatic hyperplasia, migraine, insomnia, bipolar disorder, idiopathic pulmonary fibrosis, allergies and pain management. More information is available about the company at

IntelGenx Corp. (IGXT) Stock Quote and News:

Disclaimer: Neither nor its officers, directors, partners, employees or anyone involved in the publication of the website or newsletters (“us” or “we”) is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. Further, we are not qualified to provide any investment advice and we make no recommendation to purchase or sell any securities. The prior article is published as information only for our readers. is a third party publisher of news and research. Our site does not make recommendations, but offers information portals to research news, articles, stock lists and recent research. Nothing on our site should be construed as an offer or solicitation to buy or sell products or securities. This site is sometimes compensated by featured companies, news submissions and online advertising. Viper Enterprises, LLC (parent company of OTC Showcase) has received no compensation for this article from and owns no shares of the aforementioned company(ies). Please read and fully understand our entire disclaimer at

Stay Informed

Receive the OTCS Newsletter *


* required

Dana-Farber to Host Cellceutix Trials

Cellceutix Corporation (CTIX)
Cellceutix Corporation has filed its Investigational New Drug application with the FDA. Dana-Farber and Beth Israel Deaconess Medical Center will be hosting the clinical trials for Kevetrin, Cellceutix's novel cancer drug. Read more news and get a stock quote.

Diabetes Rate Growing Exponentially

According to the International Diabetes Federation, more than 500 million people will be diagnosed with diabetes in the next two decades, a more than 50 percent increase from today. Technologies are available presently to help manage the frequency, complications and costs associated with diabetes. Read the complete article to learn more.

Contacts and information

Have an opinion or news that you want to share?

Social networks

Most popular categories

© 2011 Viper Enterprises, LLC. All rights reserved.